BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pendopharm readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Pendopharm's drugs run\, from Cli
 nicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07706764-10863@assetmemo.bio
DTSTAMP:20261121T004535Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Yorvipath (palopegteriparatide): Phase 3 readout est. (NCT07706764)
DESCRIPTION:Yorvipath (palopegteriparatide)\, phase 3\, Hypoparathyroidism.
 \nStudy: A Study to Test the Effects and Safety of Palopegteriparatide in 
 Adolescents With Long-term Hypoparathyroidism\nEstimated primary completio
 n: August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/palop
 egteriparatide#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07706764
URL:https://assetmemo.bio/drug/palopegteriparatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
